Literature DB >> 8695987

Outcome of idiopathic membranoproliferative glomerulonephritis in children. Arbeitsgemeinschaft Pädiatrische Nephrologie.

R Schwertz1, R de Jong, N Gretz, M Kirschfink, D Anders, K Schärer.   

Abstract

The aim of this multicentre study was to analyse the long-term outcome of idiopathic membranoproliferative glomerulonephritis (MPGN) according to histological type and to the presence of C3 nephritic factor. Fifty patients aged 2-14 years at the onset of the study were followed over 2-20 years; 26 patients had MPGN type I, 17 had type II and 7 had type III. Treatment was variable. At the last observation, 30 patients had reached terminal and four pre-terminal renal failure. The median survival probability until renal death was 15.3, 8.7 and 15.9 years for disease types I, II and III respectively (difference between MPGN types I + III versus type II: p = 0.013). The presence of an initial nephrotic syndrome was associated with a more rapid progression (p = 0.018). C3 nephritic factor was of no prognostic value. We conclude that the outcome of MPGN mainly depends on the histological type observed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695987     DOI: 10.1111/j.1651-2227.1996.tb14022.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  10 in total

1.  Recurrence of membranoproliferative glomerulonephritis after renal transplantation in Denys-Drash.

Authors:  Thomas J Neuhaus; Walter Arnold; Ariana Gaspert; Helmut Hopfer; Andreas Fischer
Journal:  Pediatr Nephrol       Date:  2010-10-28       Impact factor: 3.714

2.  Trends in pediatric primary membranoproliferative glomerulonephritis costs and complications.

Authors:  Chang-Ching Wei; Wei Wang; William E Smoyer; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2012-07-18       Impact factor: 3.714

3.  MPGN II--genetically determined by defective complement regulation?

Authors:  Christoph Licht; Ursula Schlötzer-Schrehardt; Michael Kirschfink; Peter F Zipfel; Bernd Hoppe
Journal:  Pediatr Nephrol       Date:  2006-09-23       Impact factor: 3.714

4.  Clinical features and outcomes of 98 children and adults with dense deposit disease.

Authors:  Der-Fa Lu; Mikyung Moon; Lynne D Lanning; Ann Marie McCarthy; Richard J H Smith
Journal:  Pediatr Nephrol       Date:  2011-11-22       Impact factor: 3.714

5.  Nephritic factor and recurrence in the renal transplant of membranoproliferative glomerulonephritis type II.

Authors:  Clark D West; John J Bissler
Journal:  Pediatr Nephrol       Date:  2008-07-02       Impact factor: 3.714

6.  C3-glomerulonephritis in New Zealand - a case series.

Authors:  Luke J Sutherland; Hari Talreja
Journal:  BMC Nephrol       Date:  2020-09-17       Impact factor: 2.388

7.  Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: change in treatment modality? A report of a case series.

Authors:  Giuseppina Spartà; Ariana Gaspert; Thomas J Neuhaus; Marcus Weitz; Nilufar Mohebbi; Urs Odermatt; Peter F Zipfel; Carsten Bergmann; Guido F Laube
Journal:  Clin Kidney J       Date:  2018-02-28

8.  Eculizumab for pediatric dense deposit disease: A case report and literature review.

Authors:  Katsuaki Kasahara; Yoshimitsu Gotoh; Hisakazu Majima; Asami Takeda; Masashi Mizuno
Journal:  Clin Nephrol Case Stud       Date:  2020-12-10

9.  Dense deposit disease in Korean children: a multicenter clinicopathologic study.

Authors:  Se Jin Park; Yong-Jin Kim; Tae-Sun Ha; Beom Jin Lim; Hyeon Joo Jeong; Yong Hoon Park; Dae Yeol Lee; Pyung Kil Kim; Kyo Sun Kim; Woo Yeong Chung; Jae Il Shin
Journal:  J Korean Med Sci       Date:  2012-10-02       Impact factor: 2.153

Review 10.  Dense deposit disease and C3 glomerulopathy.

Authors:  Thomas D Barbour; Matthew C Pickering; H Terence Cook
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.